advertisement

Topcon

Abstract #11453 Published in IGR 6-3

Intravitreal triamcinolone acetonide and intraocular pressure

Smithen LM; Ober MD; Maranan L; Spaide RF
American Journal of Ophthalmology 2004; 138: 740-743


PURPOSE: To analyze the incidence of intraocular pressure (IOP) elevation following intravitreal triamcinolone injection. DESIGN: Retrospective observational case series. METHODS: Charts of patients undergoing intravitreal triamcinolone injection in one clinical practice were reviewed. A pressure elevation was defined as a pressure of 24 mmHg or higher during follow-up. RESULTS: There were 89 patients with a mean age of 76.4 years. The mean baseline IOP was 14.9 mmHg with a mean change of 8.0 mmHg. Thirty-six patients (40.4%) experienced a pressure elevation to 24 mmHg or higher at a mean of 100.6 days (SD = 83.1 day) after treatment. Of nonglaucomatous patients with baseline IOP of 15 mmHg or above, 60.0% experienced a pressure elevation, compared with only 22.7% of those with baseline pressures below 15 mmHg (relative risk = 2.1, P < .01). In glaucoma patients, 6 of 12 (50%) experienced a pressure elevation, and this elevation was not correlated with baseline pressure. Thirty-two patients (36.0%) received repeat injections, and there was no difference in the incidence of procedure elevation in patients receiving multiple injections versus those receiving a single injection. Pressure elevation was controlled with topical medications in all patients. CONCLUSIONS: IOP elevation after intravitreal triamcinolone injection is common and may take an extended period of time to manifest. The proportion of patients who developed a pressure elevation to at least 24 mmHg was much higher for those with baseline IOP 15 mmHg or greater.

Dr. Lindsay M. Smithen, Vitreous, Retina, Macula Consultants of New York, and the LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Hospital, New York, NY, USA


Classification:

9.4.1 Steroid-induced glaucoma (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders)



Issue 6-3

Change Issue


advertisement

Oculus